Want to see KPRX full AI Analyst Report?
Top Page
Kiora Pharmaceuticals
(NASDAQ:KPRX)
Select Model
Select Model
Rating:47Neutral
Price Target:
$2.50
▼(-3.47% Downside)
Action:Reiterated
Date:09/08/26
The score is held down primarily by weak financial performance (zero TTM revenue, net losses, and sustained free-cash-flow burn) despite low leverage. Technicals are neutral-to-slightly weak near term, while corporate events provide some offset through partnering and pipeline/leadership progress; valuation remains constrained by negative earnings and no dividend data.
Positive Factors
Very low leverage
Minimal debt reduces solvency and refinancing pressure, preserving financial flexibility while Kiora advances its pipeline. The limited interest burden also leaves more of the equity base available to support clinical development and strategic priorities over the coming quarters.
Negative Factors
No current operating revenue
Zero trailing revenue means Kiora currently lacks an established product-sales engine to fund operations. Combined with recurring losses, this leaves performance dependent on clinical progress, partnerships or future financing rather than a durable commercial revenue base.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt reduces solvency and refinancing pressure, preserving financial flexibility while Kiora advances its pipeline. The limited interest burden also leaves more of the equity base available to support clinical development and strategic priorities over the coming quarters.
Read all positive factors
Kiora Pharmaceuticals (KPRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$11.28M
Dividend YieldN/A
Average Volume (3M)14.34K
Price to Earnings (P/E)―
Beta (1Y)1.08
Revenue GrowthN/A
EPS Growth19.38%
CountryUS
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.50
Shares Outstanding4,424,387
10 Day Avg. Volume11,424
30 Day Avg. Volume14,341
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$12.00Price Target Upside363.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.66
Revenue Forecast (FY)$1.50M
Kiora Pharmaceuticals Business Overview & Revenue Model
Company Description
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic can...
How the Company Makes Money
As a clinical-stage biotech, Kiora Pharmaceuticals does not have an established, recurring product-sales business in the way commercial-stage pharmaceutical companies do. Publicly available information about Kiora’s specific, ongoing revenue-gener...
Kiora Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
23
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 16.00M | 0.00 | 0.00 | 0.00 |
| Gross Profit | -41.98K | -24.80K | 16.00M | 0.00 | 0.00 | 0.00 |
| EBITDA | -12.22M | -12.07M | 5.70M | -12.36M | -13.65M | -13.91M |
| Net Income | -10.99M | -10.84M | 3.59M | -12.51M | -13.58M | -13.77M |
Balance Sheet | ||||||
| Total Assets | 23.78M | 24.25M | 36.48M | 13.71M | 18.68M | 20.13M |
| Cash, Cash Equivalents and Short-Term Investments | 16.84M | 17.09M | 26.79M | 2.45M | 5.96M | 7.85M |
| Total Debt | 333.02K | 368.26K | 57.17K | 106.89K | 105.78K | 209.41K |
| Total Liabilities | 6.92M | 8.13M | 10.72M | 7.60M | 7.27M | 5.55M |
| Stockholders Equity | 16.86M | 16.13M | 25.76M | 6.11M | 11.41M | 14.58M |
Cash Flow | ||||||
| Free Cash Flow | -8.61M | -10.07M | 8.55M | -9.56M | -10.43M | -10.74M |
| Operating Cash Flow | -8.51M | -9.96M | 8.56M | -9.56M | -10.43M | -10.68M |
| Investing Cash Flow | 9.60M | 14.43M | -22.66M | 0.00 | 6.38K | -157.02K |
| Financing Cash Flow | 4.92M | 265.65K | 15.50M | 5.97M | 8.62M | 17.58M |
Kiora Pharmaceuticals Technical Analysis
Negative
2.59
Price Trends
2.57
Negative
2.56
Negative
2.33
Positive
Market Momentum
>-0.01
Positive
44.22
Neutral
16.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KPRX, the sentiment is Negative. The current price of 2.59 is below the 20-day moving average (MA) of 2.59, above the 50-day MA of 2.57, and above the 200-day MA of 2.33, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.22 is Neutral, neither overbought nor oversold. The STOCH value of 16.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KPRX.
Kiora Pharmaceuticals Risk Analysis
Kiora Pharmaceuticals disclosed 50 risk factors in its most recent earnings report. Kiora Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Kiora Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $16.35M | -1.46 | -569.36% | ― | ― | 63.72% | |
47 Neutral | $11.28M | -1.00 | -63.39% | ― | ― | 19.38% | |
46 Neutral | $11.83M | -0.61 | -91.18% | ― | ― | 81.87% | |
42 Neutral | $271.78M | -0.05 | -443.08% | ― | ― | 75.09% | |
41 Neutral | $81.76M | -0.13 | -423.84% | ― | -8.47% | 25.62% | |
40 Underperform | $9.81M | >-0.01 | -222.32% | ― | ― | 78.25% |
* Healthcare Sector Average
KPRX
Kiora Pharmaceuticals
2.51
-0.12
-4.56%
GTBP
GT Biopharma
5.24
-13.45
-71.97%
KALA
KALA BIO
0.54
-699.46
-99.92%
BRTX
BioRestorative Therapies
2.80
-28.60
-91.08%
BCDA
BioCardia
1.11
-1.00
-47.39%
INAB
IN8bio
1.14
-0.87
-43.37%
Kiora Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Kiora Pharmaceuticals Bolsters Leadership in Clinical Development
Positive
Sep 8, 2026
On September 8, 2026, Kiora Pharmaceuticals appointed Keith J. Lane as Executive Vice President of Clinical Development and Regulatory Affairs, strengthening its leadership in ophthalmic drug development. Lane brings more than 20 years of experien...
Business Operations and StrategyPrivate Placements and Financing
Kiora Licenses KIO-301 Rights in South Korea
Positive
Aug 19, 2026
On August 20, 2026, Kiora Pharmaceuticals entered an exclusive license and development agreement with Chong Kun Dang Pharmaceutical Corporation granting CKD rights to develop, manufacture and commercialize its KIO-301 molecular photoswitch in Sout...
Business Operations and StrategyProduct-Related Announcements
Kiora Showcases Promising Preclinical Epilepsy Data for KIO-300
Positive
Jun 18, 2026
On June 18, 2026, Kiora Pharmaceuticals reported preclinical data showing that its ion channel modulator KIO-300 significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy model. The data, presen...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan
Positive
Jun 11, 2026
On June 10, 2026, Kiora Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders, where shareholders approved an amendment to the 2024 Equity Incentive Plan to add 1,500,000 shares of common stock for potential issuance. The meeting also...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.